Search Results for "Sjogren A Belimumab"

06:57 EDT 25th April 2015 | BioPortfolio

Matching Channels

None

Matching News

Molecule identified that could lead to new drugs for lupus and Sjogren’s

An inflammatory molecule that appears to play an essential role in systemic lupus erythematosus has been identified by a team from Massachusetts General Hospital, they report in Nature Immunology. The...

Role of Novel Hepatitis Delta Virus Variant in Sjogren’s Syndrome

Aldeyra Therapeutics Submits IND Filing to FDA for Clinical Testing of NS2 in Patients With Sjogren-Larsson Syndrome

LEXINGTON, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free...

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Revision: 10, Authorised

Aldeyra Therapeutics Announces First Patient Enrolled in Sjogren-Larsson Syndrome Phase II Clinical Trial

LEXINGTON, Mass., March 24, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to fr...

Aldeyra Therapeutics Announces Collaboration With the National Organization for Rare Disorders to Enhance Awareness for Sjogren-Larsson Syndrome Patients

LEXINGTON, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free...

Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Sjogren-Larsson Syndrome at the 2015 Society for Inherited Metabolic Disorders Annual Meeting

LEXINGTON, Mass., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to fre...

B-Cell Antibody Modestly Improves Sjogren?s Symptoms (CME/CE)

(MedPage Today) -- Study says further randomized, controlled trials needed to gauge effectiveness.

Matching PubMed Articles

Update on belimumab for the management of systemic lupus erythematosus.

Introduction: Belimumab is a fully humanised mAb against B lymphocyte stimulator (B-LyS). It is the first biological drug to be licensed and approved by the US FDA and the European Medicines Evaluatio...

Belimumab and the measurement of fatigue.

New treatments for inflammatory rheumatic disease.

As our understanding of the pathogenesis of autoimmune diseases is growing, new therapies are being developed to target disease-specific pathways. Since the introduction of etanercept in 1998, several...

IL-22 receptor 1 is over-expressed in primary Sjogren's Syndrome and Sjogren-associated non-Hodgkin lymphomas and is regulated by IL-18.

Aim of this study was to better elucidate the role of interleukin (IL)-18 in modulating the IL-22 pathway in primary Sjogren's syndrome (pSS) patients and in pSS-associated lymphomas.

Neutralization of NK cell-derived B cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.

NK cells are cytotoxic lymphocytes that substantially contribute to the therapeutic benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B cell malignancies. In chro...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement